|
| COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms |
|
https://doi.org/10.18632/oncotarget.28824
Charlotte Kuperwasser, Wafik S. El-Deiry
|
| 1-29 |
|
| Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53 |
|
https://doi.org/10.18632/oncotarget.28823
Wafik S. El-Deiry
|
| 30-33 |
|
| Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms |
|
https://doi.org/10.18632/oncotarget.28827
Patrizia Gentilini, Janci C. Lindsay, Nafuko Konishi, Masanori Fukushima, Panagis Polykretis
|
| 34-49 |
|
| Censorship in science: How publishing decisions could have shaped the perceived “general consensus” on COVID-19 vaccine safety and efficacy |
|
https://doi.org/10.18632/oncotarget.28829
Panagis Polykretis, Janci C. Lindsay, Patrizia Gentilini, Nafuko Konishi, Masanori Fukushima
|
| 50-53 |
|
| CAR-T therapy: Trailblazing CAR(ing) in cancer treatment |
|
https://doi.org/10.18632/oncotarget.28836
Uzma Saqib, Monika Pandey, Krishnan Hajela
|
| 54-56 |
|
| Correction: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells |
|
https://doi.org/10.18632/oncotarget.28846
Steven A. Greenberg
|
| 57-58 |
|
| CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer |
|
https://doi.org/10.18632/oncotarget.28826
Allison Makovec, John T. Phoenix, Hannah E. Bergom, Ella Boytim, Ava P. Gustafson, Aiden Deacon, Sydney Tape, Atef Ali, Megan Ludwig, Samuel P. Pitzen, David Moline, Camden Richter, Hudson Longie, Mei-Chi Su, Sampreeti Jena, Pornlada Likasitwatanakul, Justin M. Drake, R. Stephanie Huang, William C. Hahn, Jonathan P. Rennhack, Scott M. Dehm, Steven Kregel, Emmanuel S. Antonarakis, Justin Hwang
|
| 59-73 |
|
| Correction: Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation |
|
https://doi.org/10.18632/oncotarget.28845
Antonio Bilancio, Paola Bontempo, Marzia Di Donato, Mariarosaria Conte, Pia Giovannelli, Lucia Altucci, Antimo Migliaccio, Gabriella Castoria
|
| 74-75 |
|
| Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism |
|
https://doi.org/10.18632/oncotarget.28844
Claudia Fumarola, Daniele Cretella, Silvia La Monica, Mara A. Bonelli, Roberta Alfieri, Cristina Caffarra, Federico Quaini, Denise Madeddu, Angela Falco, Andrea Cavazzoni, Graziana Digiacomo, Giulia Mazzaschi, Valentina Vivo, Elisabetta Barocelli, Marcello Tiseo, Pier Giorgio Petronini, Andrea Ardizzoni
|
| 76-77 |
|
| The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells |
|
https://doi.org/10.18632/oncotarget.28861
Michael R. Booth, Laurence Booth, Jane L. Roberts, John M. Kirkwood, Paul Dent
|
| 78-89 |
|
| Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses |
|
https://doi.org/10.18632/oncotarget.28851
Kayode Ahmed, Juan E. Núñez-Ríos
|
| 90-118 |
|
| Retraction: miR-135a promotes gastric cancer progression and resistance to oxaliplatin |
|
https://doi.org/10.18632/oncotarget.28835
Lin-Hai Yan, Zhi-Ning Chen, Li-Li, Jia Chen, Wen-E Wei, Xian-Wei Mo, Yu-Zhou Qin, Yuan Lin, Jian-Si Chen
|
| 119-119 |
|
| Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials |
|
https://doi.org/10.18632/oncotarget.28855
Maryam Aleid, Fatimah Aleid, Daniah Allbdi, Ahmad Rchdeih, Dhai Almuteri, Abdulelah Almesned, Samaa Alotab, Yumna AlMishary, Galia Alsamman, Atlal Abusanad
|
| 120-135 |
|
| Correction: LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions |
|
https://doi.org/10.18632/oncotarget.28843
Fakeng Liu, Rui Jin, Xiuju Liu, Henry Huang, Scott C. Wilkinson, Diansheng Zhong, Fadlo R. Khuri, Haian Fu, Adam Marcus, Yulong He, Wei Zhou
|
| 136-136 |
|
| Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer |
|
https://doi.org/10.18632/oncotarget.28842
Gonzalo Sequeira, Silvia I Vanzulli, Paola Rojas, Caroline Lamb, Lucas Colombo, María May, Alfredo Molinolo, Claudia Lanari
|
| 137-138 |
|
| Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings |
|
https://doi.org/10.18632/oncotarget.28856
Pragnesh Parmar, Gunvanti Rathod
|
| 139-155 |
|
| Retraction: Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis |
|
https://doi.org/10.18632/oncotarget.28834
Lili Yang, Gongliang Guo, Liqun Sun, Chenhao Li, Haipeng Zhang
|
| 156-156 |
|
| Epigenetic dysregulation and biological function of PDX1 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.28854
Tayo A. Adeyika, Anju Datturgi, Yehnara Ettinoffe, Somiranjan Ghosh, Christopher Albanese, Bernard Kwabi-Addo
|
| 157-172 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
